Refine Search

New Search

Result: 1

(searched for: doi:10.17352/ahcrr.000036)
Save to Scifeed
Page of 1
Articles per Page
by
Show export options
  Select all
Ladak Nurfiza, Csehak Kenneth, Chan Justin, Moen Farnoush
Archives of Hematology Case Reports and Reviews, Volume 7, pp 006-008; https://doi.org/10.17352/ahcrr.000036

Abstract:
Hemophagocytic Lymphohistiocytosis (HLH) in coronavirus disease 2019 (COVID-19) is a recognized complication of severe illness. However, this phenomenon has been reported most often in the setting of acute infection. Here we present a case of a patient with a history of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection that subsequently developed HLH weeks after treatment of COVID-19 and discharges from the hospital. Upon re-admission, work-up demonstrated the patient was experiencing Epstein-Barr virus (EBV) reactivation. As EBV infection is a known etiological trigger of HLH, this case provides an alternative mechanism for HLH seen in patients with a history of COVID-19 infection who present after the resolution of acute symptomatology.
Page of 1
Articles per Page
by
Show export options
  Select all
Back to Top Top